Treeway has reported positive results from a Phase I clinical trial designed to analyse the bioavailability of TW001 in comparison with Radicavaâ for the treatment of amyotrophic lateral sclerosis (ALS).

Findings of the trial have showed increased bioavailability of TW001 in a single-dose treatment, with no safety concerns developed within the subject group.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Theresults have implied the potential of TW001 to improve treatment strategies for ALS patients.

During the randomised cross-over comparative bioavailability trial, a single oral dose of 140mg of TW001 was tested against a one-hour intravenous infusion of 60mg of Radicavaâin 18 healthy subjects.

Treeway chief development officer Ronald van der Geest said: “It is Treeway’s mission to identify novel treatment routes for ALS patients and we believe that this study indicates that an oral formulation of edavarone may offer patients a better quality-of-life through a simpler and more effective route of administration.

“We can initiate a pivotal Phase lll study and move rapidly toward bringing TW001 to patients.”

“Given the nature of this programme and based on the positive results we have seen in this comparative study, we can initiate a pivotal Phase lll study and move rapidly toward bringing TW001 to patients.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

TW001, an oral formulation of edaravone, has been developed as a disease-modifying drug for all phenotypes of ALS, and can be used daily to improve patient convenience.

ALS is also called Lou Gehrig’s Disease, which is a progressive neurodegenerative rare condition that causes muscle weakness, disability and eventually death.

The disease, which most frequently attacks people between the ages of 40 and 60, is estimated to affect nearly two people per 100,000 annually.

There is currently no treatment available for ALS.